| Literature DB >> 24137338 |
Cristiana Simionescu1, Claudiu Mărgăritescu, Alex Stepan, Daniel Pirici, Raluca Ciurea, Nicolae Cernea.
Abstract
The present study aimed to observe and compare the values of microvessel density (MVD), mast cell microdensity (McMD) and macrophage microdensity (MphMD) in intratumoral areas compared with the advancing edges, and to assess any correlations between these values and the degree and stage of the neoplasia. The cases of 52 patients who were diagnosed with endometrial carcinoma between 2003 and 2011 were analyzed, the majority of which were in the first stage of the disease (44 cases). Double sequential immunohistochemistry and the hot-spot counting method were used to assess the MVD (CD105+ MVD), McMD [tryptase+ (Try+) McMD] and MphMD (CD68+ MphMD) densities. The χ2 test, paired Student's t-test and the Pearson correlation index were used to assess the significance of the results. A weak correlation was observed at the advancing edge only, between CD105+ MVD and Try+ McMD (P=0.039). No significant differences were identified in the analysis of CD105+ MVD, Try+ McMD and CD68+ MphMD, but wide variations in their distribution were observed. Depending on the tumor stage, CD105+ MVD exhibited an intratumoral, indirect correlation with Try+ McMD for stage IA (P=0.026) and II (P=0.013) tumors. CD105+ MVD presented an indirect correlation with CD68+ MphMD in stage IB tumors (P=0.016) and at the advancing edge for well-differentiated tumors (P=0.027). An analysis of the correlation between CD68+ MphMD and Try+ McMD indicated that the intratumoral levels of CD68+ MphMD were directly proportional with the Try+ McMD values in well-differentiated (P=0.005) and stage II (P=0.012) tumors, while at the front of the invasion, this correlation was indirect (P=0.010) in stage II tumors. In endometrioid endometrial carcinoma (EEC), angiogenesis is at its most active at the advancing edge of the tumor, where mast cells play a pro-angiogenic role.Entities:
Keywords: endometrial carcinoma; macrophages; mast cells; tumor angiogenesis
Year: 2013 PMID: 24137338 PMCID: PMC3789045 DOI: 10.3892/ol.2013.1412
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Panel of antibodies used for the immunohistochemistry.
| Antibody | Clone, manufacturer | Dilution | Antigenic retrieval | External positive control |
|---|---|---|---|---|
| CD105 (endoglin) | Polyclonal, Thermo Scientific | 1:50 | Citrate, pH 6 | Kidney |
| Mast cell tryptase | AA1, Dako | 1:100 | Citrate, pH 6 | Skin |
| CD68 | KP1, Dako | 1:50 | Citrate, pH 6 | Skin |
Thermo Scientific (Motortech, Timisoara, Romania); Dako (Redox Bucharest, Romania).
Figure 1.Endometrial carcinoma. Mast cells and microvessels from (A) the invasion front and (B) the intratumoral area; double immunohistochemistry for tryptase (AP-Fast Red; red and CD105 (HRP-DAB; brown). Macrophages and microvessels from (C) the invasion front and (D) intratumoral area; double immunohistochemistry for CD68 (AP-Fast Red; red) and CD105 (HRP-DAB; brown). Magnification, x100.
Correlations of MVD, McMD and MphMD in EEC with clinico-morphological investigated parameters.
| Parameter | Tumoral degree | Tumoral stage | |||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| WD | MD | PD | IA | IB | II | III | |
| No. | 30 | 13 | 9 | 17 | 27 | 5 | 3 |
| MVD | |||||||
| IT | 11.8±4.2 | 12.8±3.2 | 16.2±6.4 | 13.9±5.6 | 12.2±4.5 | 14.0±2.0 | 10.3±0.6 |
| AE | 20.1±6.7 | 17.5±5.0 | 22.8±6.1 | 19.0±7.2 | 20.1±6.6 | 21.2±4.2 | 21.7±1.5 |
| P-value | 1.938×10−7 | 0.004 | 0.019 | 0.014 | 1.875×10−6 | 0.004 | 0.000 |
| McMD | |||||||
| IT | 3.7±3.3 | 6.8±3.7 | 5.3±4.7 | 4.4±3.1 | 5.2±4.2 | 5.0±5.5 | 2.3±0.6 |
| AE | 7.5±5.2 | 5.8±2.8 | 9.7±3.8 | 9.0±5.6 | 6.8±4.4 | 5.6±1.1 | 8.0±1.0 |
| P-value | 0.000 | 0.221 | 0.020 | 0.002 | 0.088 | 0.408 | 0.000 |
| MphMD | |||||||
| IT | 13.7±8.9 | 10.2±10.9 | 4.6±2.0 | 11.0±8.2 | 11.3±7.9 | 17.4±17.7 | 2.3±0.6 |
| AE | 9.6±12.6 | 6.8±6.6 | 6.5±3.9 | 3.2±3.6 | 12.3±12.5 | 7.2±5.2 | 4.0±5.2 |
| P-value | 0.075 | 0.169 | 0.108 | 0.000 | 0.358 | 0.125 | 0.305 |
EEC, endometrioid endometrial cancer; MVD, microvessel density; MphMD, macrophage microdensity; McMD, mast cell microdensity; IT, intratumoral; AE, advancing edge; WD, well-differentiated; MD, moderate-differentiated; PD, poor-differentiated. P-values were obtained by Student’s t-test. All data, with the exception of No., are presented as mean ± standard deviation.
Figure 2.The distribution of vessels (CD105+), macrophages (CD68+) and mast cells (TRY) depending on tumor (A) differentiation degree and (B) stage. TRY, tryptase; IT, intratumoral; AE, advancing edge; WD, well-differentiated; MD, moderately-differentiated; PD, poorly-differentiated. Error bars represent standard deviation. *P<0.05; **P<0.01; ***P<0.001.